HER2+ Treatment via Concurrent OR Sequential Treatment

NATSGSG

Hello Everyone:

As a new HER2+ breast cancer patient soon to be receiving treatment after my surgery coming Wed, March 25, I wish to share a report by PHARMAC, the New Zealand Pharmaceutical Management Agency, that 9 weeks concurrent treatment of Herception with docetaxel provides the the most "synergistic benefit of choosing a lower dosage level than was in international practice." That's the treatment plan I will be asking my MD to give to me after surgery.

As we are all aware, chemotheraphy while killing our cancerous cells, also harms our normal cell. I want to find the optimal treatment plan for myself as this is one of the ways I can take charge of my body. I do not want to just take whatever my MD prescribe without knowing the consequence to me physically as I have a teenage daughter whom I want to spend more time with.

If you are HER2+, please go to this link below and read up as much as you can before blindly accepting any form of therapy. There are proven clinical trials reported in there, supported by statistics that 9 weeks is a full treatment regimen. This was proven in an RCT conducted by International Breast Cancer Specialist, Doctor and Prof. Heikke Joensuu of the University of Finland in his FinHer report.  Please be sure to read them. One thing I learn from all these reading is NOT to believe everything pharmaceutical says or claim. Their motivation may not be in harmony with us Cancer Patients. You will be amazed of the many things you can learn from these links, and reports.

1) This is the link to the NZ Pharmaceutical Management Agency publishing the full results of their findings

http://www.pharmac.health.nz/search?search_q=SOLD STUDY RESULT&start=0http://www.pharmac.health.nz/search?search_q=SOLD STUDY RESULT&start=0

2) This is the Auckland Women's Health Council's Report on a shorter course of Herceptin treatment beats longer course

http://www.womenshealthcouncil.org.nz/Features/Hot+Topics/Herceptin.html

NOTE: FDA has approved several drugs for HER2+ cancer patients. Among them, they are:

1) Herceptin by Roche,  Swiss Pharmaceutical Co. (for early stage cancer), marketed in the USA by Genentech

(2) Perjeta by Roche, in combination with other drugs,  for late stage cancer

 (3) Tykerb by Glaxo-Smith Kline (GSK)  in combination of other drugs  (for advanced or metastatic breast cancer per FDA website)

All the best to us all in our road towards early recovery. May God Bless You, Your Family & Friends who continue to be very supportive of us.